David Hudesman MD, FACG
Associate ProfessorNew York, United States
As the therapeutic armamentarium for IBD grows, it becomes increasing important to gain an understanding on the positioning of various advance therapies (biologics and small molecules) used in a way that can maximize drug efficacy and patient outcome.
Bearing in mind that a previous therapy may have an influence on the maximal efficacy of subsequent drug, this means not only looking at comparative efficacy and safety but also the sequencing of each medicine when choosing first line biologic or small molecule.
In this presentation, we will look at the some of the evidence in the literature that can help guide us in choosing the right therapy for the right patient at the right time and sequence to maximize patient outcome.
Prof. David Hudesman is an Associate Professor of Medicine at NYU School of Medicine, attending gastroenterologist and director of Inflammatory Bowel Disease Center at NYU Langone Health.
He specializes in the diagnosis and treatment of inflammatory bowel disease (IBD) and in the provision of integrated, seamless, patient-centered care. His research is focused on disease monitoring, patient outcomes, and the evaluation of new medical therapies for the treatment of both Crohn’s disease and ulcerative colitis.
Prof. Hudesman serves on the Research Committee of the American College of Gastroenterology, and the Professional Education Committee of the Crohn’s and Colitis Foundation. He is a reviewer for multiple scientific gastroenterology journals, including Clinical Gastroenterology and Hepatology and Inflammatory Bowel Diseases.
To access this presentation, please login and click on the 'ENROLL TO WATCH' blue button by the right, on this page. To create a new account, please click here.
